Despite the explosion in popularity of cannabinoid products, many questions remain regarding their efficacy and long-term use. DW investigates potential applications and concerns regarding the use of cannabinoids in dermatology.
Most dermatologists have good relationships with their patients’ pharmacists, but there can be bumps in the road due to miscommunication, lack of communication, and inadequate education of pharmacists about dermatologic conditions.
“Good leadership is not about being in charge, it’s about taking care of those in your charge.” Learn if the servant leadership model right for you.
Alex Miller, MD, offers a review of Mohs qualifying, documentation, and billing criteria.
Esther Freeman, MD, PhD, discusses the new COVID-19 Dermatology Registry.
James Zalla, MD, discusses his efforts to keep his practice afloat during the COVID-19 pandemic.
DW offers a snapshot on the burden of prior authorization in the United States.
Are you exempt from the COVID-19 FMLA and paid sick leave provisions?
Will your non-compete dictate where you practice next?
What do you need to know about employment laws when considering a staff furlough?
How to protect yourself from physician identity theft.
Physician editor Kathryn Schwarzenberger, MD, previews this month’s issue.
Members of DW’s Editorial Advisory Workgroup share exciting news from across the specialty.
What resources does the Academy have on telemedicine?
Academy President Bruce Thiers, MD, offers his thoughts on rebuilding after COVID-19.